Therapeutic utility of cannabinoid receptor type 2 (CB2) selective agonists

Journal of Medicinal Chemistry

Volumn 56, Issue 21, 2013, Pages 8224-8256

  Han, Sangdon ^a   Thatte, Jayant ^a   Buzard, Daniel J ^a   Jones, Robert M ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 8 (2 CHLOROPHENYL) 2 METHYL 6 (4 METHYLPIPERAZIN 1 YL) 9 (TETRAHYDRO 2H PYRAN 4 YL) 9H PURINE; [4 [(3 CHLOROPHENYL)AMINO] 1 METHYL 1H PYRROLO[3,2 C]PYRIDIN 7 YL)(MORPHOLINO)METHANONE; AJULEMIC ACID; ANALGESIC AGENT; ANANDAMIDE; CANNABIDIOL; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; CANNABINOR; DELTA9 TETRAHYDROCANNABINOL DERIVATIVE; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; GSK 55441A; JBT 101; JWH 056; JWH 151; L 759632; L 759633; L 759656; LEVONANTRADOL; LY 2828360; NABILONE; NOLADIN ETHER; O 1057; O 1966; PRS 211375; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROHAMINE;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; ANALGESIA; ANALGESIC ACTIVITY; ATHEROSCLEROSIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLITIS; COUGHING; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRACT; HUMAN; HYPERALGESIA; IMMUNE SYSTEM; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIS; OSTEOLYSIS; PAIN; PERIPHERAL NERVOUS SYSTEM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUANTITATIVE STRUCTURE ACTIVITY RELATION; REPERFUSION INJURY; REVIEW; SKIN ALLERGY; T LYMPHOCYTE; TRAUMATIC BRAIN INJURY; UVEORETINITIS;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84887974190     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm4005626     Document Type: Review

References (346)

1. Gaoni, Y.; Mechoulam, R. Isolation, structure, and partial synthesis of an active constitutent of hashish J. Am. Chem. Soc. 1964, 86, 1646-1647
2. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
3. Brown, S. M.; Wager-Miller, J.; Mackie, K. Cloning and molecular characterization of the rat CB2 cannabinoid receptor Biochim. Biophys. Acta 2002, 1576, 255-264
4. Munro, S.; Thomas, K. L.; Bu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
5. Brown, A. J. Novel cannabinoid receptors Br. J. Pharmacol. 2007, 152, 567-575
6. Mackie, K.; Stella, N. Cannabinoid receptors and endocannabinoids: evidence for new players AAPS J. 2006, 8, E298-E306
7. Overton, H. A.; Babbs, A. J.; Doel, S. M.; Fyfe, M. C.; Gardner, L. S.; Griffin, G.; Jackson, H. C.; Procter, M. J.; Rasamison, C. M.; Tang-Christensen, M.; Widdowson, P. S.; Williams, G. M.; Reynet, C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Cell Metab. 2006, 3, 167-175
8. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor Br. J. Pharmacol. 2007, 152, 1092-1101
9. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor Biochem. Biophys. Res. Commun. 2007, 362, 928-934
10. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl- sn -glycero-3-phosphoinositol: a possible natural ligand for GPR55 J. Biochem. 2009, 145, 13-20
11. Ross, R. A. The enigmatic pharmacology of GPR55 Trends Pharmacol. Sci. 2009, 30, 156-163
12. Jones, R. M. Discovery of agonists of the glucose dependent insulinotropic receptor, GPR119, a pancreatic beta-cell oGPCR, for the treatment of NIDDM Drugs Future 2006, 31 (Suppl. A L48
13. Slipetz, D. M.; O'Neill, G. P.; Favreau, L.; Dufresne, C.; Gallant, M.; Gareau, Y.; Guay, D.; Labelle, M.; Metters, K. M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase Mol. Pharmacol. 1995, 48, 352-361
14. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrie, B.; Rinaldi-Carmona, M.; Calandra, B.; Le, F. G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression Eur. J. Biochem. 1996, 237, 704-711
15. Sugiura, T.; Kondo, S.; Kishimoto, S.; Miyashita, T.; Nakane, S.; Kodaka, T.; Suhara, Y.; Takayama, H.; Waku, K. Evidence that 2-arachidonoylglycerol but not N -palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells J. Biol. Chem. 2000, 275, 605-612
16. Shoemaker, J. L.; Ruckle, M. B.; Mayeux, P. R.; Prather, P. L. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors J. Pharmacol. Exp. Ther. 2005, 315, 828-838
17. Bonhaus, D. W.; Chang, L. K.; Kwan, J.; Martin, G. R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses J. Pharmacol. Exp. Ther. 1998, 287, 884-888
18. Wiens, B. L.; Nelson, C. S.; Neve, K. A. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations Mol. Pharmacol. 1998, 54, 435-444
19. Berg, K. A.; Maayani, S.; Goldfarb, J.; Scaramellini, C.; Leff, P.; Clarke, W. P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus Mol. Pharmacol. 1998, 54, 94-104
20. Figini, M.; Emanueli, C.; Bertrand, C.; Sicuteri, R.; Regoli, D.; Geppetti, P. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea Br. J. Pharmacol. 1997, 121, 773-781
21. Kenakin, T. Drug efficacy at G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2002, 42, 349-379
22. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le, F. G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations Eur. J. Biochem. 1995, 232, 54-61
23. Schatz, A. R.; Lee, M.; Condie, R. B.; Pulaski, J. T.; Kaminski, N. E. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system Toxicol. Appl. Pharmacol. 1997, 142, 278-287
24. Lynn, A. B.; Herkenham, M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids J. Pharmacol. Exp. Ther. 1994, 268, 1612-1623
25. Van, S.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Di, M., V; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 2005, 310, 329-332
26. Onaivi, E. S.; Ishiguro, H.; Gong, J. P.; Patel, S.; Perchuk, A.; Meozzi, P. A.; Myers, L.; Mora, Z.; Tagliaferro, P.; Gardner, E.; Brusco, A.; Akinshola, B. E.; Liu, Q. R.; Hope, B.; Iwasaki, S.; Arinami, T.; Teasenfitz, L.; Uhl, G. R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain Ann. N.Y. Acad. Sci. 2006, 1074, 514-536
27. Ashton, J. C.; Friberg, D.; Darlington, C. L.; Smith, P. F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study Neurosci. Lett. 2006, 396, 113-116
28. Nunez, E.; Benito, C.; Pazos, M. R.; Barbachano, A.; Fajardo, O.; Gonzalez, S.; Tolon, R. M.; Romero, J. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study Synapse 2004, 53, 208-213
29. Anand, U.; Otto, W. R.; Sanchez-Herrera, D.; Facer, P.; Yiangou, Y.; Korchev, Y.; Birch, R.; Benham, C.; Bountra, C.; Chessell, I. P.; Anand, P. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons Pain 2008, 138, 667-680
30. Stander, S.; Schmelz, M.; Metze, D.; Luger, T.; Rukwied, R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin J. Dermatol. Sci. 2005, 38, 177-188
31. Benito, C.; Romero, J. P.; Tolon, R. M.; Clemente, D.; Docagne, F.; Hillard, C. J.; Guaza, C.; Romero, J. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis J. Neurosci. 2007, 27, 2396-2402
32. Richardson, D.; Pearson, R. G.; Kurian, N.; Latif, M. L.; Garle, M. J.; Barrett, D. A.; Kendall, D. A.; Scammell, B. E.; Reeve, A. J.; Chapman, V. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis Arthritis Res. Ther. 2008, 10, R43
33. Rossi, F.; Siniscalco, D.; Luongo, L.; De, P. L.; Bellini, G.; Petrosino, S.; Torella, M.; Santoro, C.; Nobili, B.; Perrotta, S.; Di, M., V; Maione, S. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption Bone 2009, 44, 476-484
34. Wright, K.; Rooney, N.; Feeney, M.; Tate, J.; Robertson, D.; Welham, M.; Ward, S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing Gastroenterology 2005, 129, 437-453
35. Iuvone, T.; De, F. D.; Di Spiezio, S. A.; D'Amico, A.; Simonetti, S.; Sparice, S.; Esposito, G.; Bifulco, G.; Insabato, L.; Nappi, C.; Guida, M. Selective CB2 up-regulation in women affected by endometrial inflammation J. Cell. Mol. Med. 2008, 12, 661-670
36. Buckley, N. E.; McCoy, K. L.; Mezey, E.; Bonner, T.; Zimmer, A.; Felder, C. C.; Glass, M.; Zimmer, A. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor Eur. J. Pharmacol. 2000, 396, 141-149
37. Ziring, D.; Wei, B.; Velazquez, P.; Schrage, M.; Buckley, N. E.; Braun, J. Formation of B and T cell subsets require the cannabinoid receptor CB2 Immunogenetics 2006, 58, 714-725
38. 1-tetrahydrocannabinol, the major active constituent of hashish Tetrahedron Lett. 1967, 8, 1109-1111
39. Devane, W. A.; Dysarz, F. A., III; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain Mol. Pharmacol. 1988, 34, 605-613
40. 2): identification of cannabinoid receptor subtype selective ligands J. Pharmacol. Exp. Ther. 1996, 278, 989-999
41. Robson, P. Therapeutic aspects of cannabis and cannabinoids Br. J. Psychiatry 2001, 178, 107-115
42. 9-tetrahydrocannabinol Euphytica 2004, 140, 73-82
43. United States Drug Enforcement Administration. http://www.justice.gov/ dea/index.shtml.
44. Silverberg, L. J. Synthesis of Cannabinoids. US7186850, 2007.
45. Busch-Petersen, J.; Hill, W. A.; Fan, P.; Khanolkar, A.; Xie, X.-Q.; Tius, M. A.; Makriyannis, A. Unsaturated side chain β-11- hydroxyhexahydrocannabinol analogs J. Med. Chem. 1996, 39, 3790-3796
46. Razdan, R. K. Structure-activity relationships in cannabinoids Pharmacol. Rev. 1986, 38, 75-149
47. Mechoulam, R.; Hanus, L.; Fride, E. Towards cannabinoid drugs-revisited Prog. Med. Chem. 1998, 35, 199-242
48. Reggio, P. H.; Seltzman, H. H.; Compton, D. R.; Prescott, W. R., Jr.; Martin, B. R. Investigation of the role of the phenolic hydroxyl in cannabinoid activity Mol. Pharmacol. 1990, 38, 854-862
49. Seltzman, H. H. Structure and receptor activity for classical cannabinoids Curr. Med. Chem. 1999, 6, 685-704
50. Reggio, P. H.; Greer, K. V.; Cox, S. M. The importance of the orientation of the C9 substituent to cannabinoid activity J. Med. Chem. 1989, 32, 1630-1635
51. Thomas, B. P.; Compton, D. R.; Martin, B. R.; Semus, S. F. Modeling the cannabinoid receptor: a three dimensinal quantitative structure-activity analysis Mol. Pharmacol. 1991, 40, 656-665
52. Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 2002, 54, 161-202
53. Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D. M.; Tremblay, N.; Weech, P. K.; Metters, K. M.; Labelle, M. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors Bioorg. Med. Chem. Lett. 1996, 6, 189-194
54. 8-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency J. Med. Chem. 2000, 43, 59-70
55. 8-tetrahydrocannabinols: a novel class of cannabinergic ligands J. Med. Chem. 2008, 51 (20) 6393-6399
56. 8- tetrahydrocannabinol Bioorg. Med. Chem. Lett. 1999, 9, 2119-2124
57. Papahatijis, D. P.; Nahmias, V. R.; Nikas, S. P.; Andreou, T.; Alapafuja, S. O.; Tsotinis, A.; Guo, J.; Fan, P.; Makriyannis, A. C1′-Cycloalkyl side chain pharmacophore in tetrahadrocannabinols J. Med. Chem. 2007, 50 (17) 4048-4060
58. 2 receptors Bioorg. Med. Chem. 2003, 11, 3121-3132
59. Lu, D.; Meng, Z.; Thakur, G. A.; Fan, P.; Steed, J.; Tartal, C. L.; Hurst, D. P.; Reggio, P. H.; Deschamps, J. R.; Parrish, D. A.; George, C.; Jaerbe, T. U. C.; Lamb, R. J.; Makriyannis, A. Adamantyl cannabinoids: a novel class of cannabinergic ligands J. Med. Chem. 2005, 48 (14) 4576-4585
60. Papahatijis, D. P.; Nikas, S. P.; Kourouli, T.; Chari, R.; Xu, W.; Pertwee, R. G.; Makriyannis, A. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1′ J. Med. Chem. 2003, 46 (15) 3221-3229
61. Krishnamurthy, M.; Ferreira, A. M.; Moore, B. M. Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids Bioorg. Med. Chem. Lett. 2003, 13 (20) 3487-3490
62. Mechoulam, R.; Lander, N.; University, A.; Zahalka, J. Syntheis of the individual, pharmacologically distinct enantiomers of a tetrahydrocannabinol derivative Tetrahedron: Asymmetry 1990, 1, 315-319
63. 1-like cannabinoid receptors J. Pharmacol. Exp. Ther. 1997, 281, 1030-1037
64. Jüttler, E.; Potrovita, I.; Tarabin, V. The cannabinoid dexanabinol is inhibitor of the nuclear factor-kappa B (NF-κB) Neuropharmacology 2004, 47, 580-592
65. Shohami, E.; Mechoulam, R. Dexanabinol (HU-211): a non-psychrotropic cannabinoid with neuroprotective properties Drug Dev. Res. 2000, 50, 211-215
66. Pharmos' Disappointing Brain-Injury Treatment. http://www.forbes.com/ 2004/12/20/cz-as-1220pharmos.html.
67. Dexanabinol in Severe Traumatic Brain Injury. http://www.clinicaltrials. gov/ct2/show/NCT00129857?term=dexanabinol&rank=1.
68. Pertwee, R. G.; Gibson, T. M.; Stevenson, L. A.; Ross, R. A.; Banner, W. K.; Saha, B.; Razdan, R. K.; Martin, B. R. O-1057, a potent water-soluble cannabinoid receptor agonist with antonociceptive properties Br. J. Pharmacol. 2000, 129, 1577-1584
69. Rhee, M.-H.; Vogel, Z.; Barg, J.; Bayewitch, M.; Levy, R.; Hanu, L.; Breuer, A.; Mechoulam, R. Cannabinoid derivatives: binding to cannabinoid receptors and inhibition of adenylcyclase J. Med. Chem. 1997, 40, 3228-3233
70. Burstein, S. H.; Audette, C. A.; Breuer, A.; Devane, W. A.; Colodner, S.; Doyle, S. A.; Mechoulam, R. Synthetic nonpsychotropic cannabinoids with potent anti-inflammatory, analgesic and leukocyte antiadhesion activities J. Med. Chem. 1992, 35, 3135-3141
71. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies, and clinical trials AAPS J. 2005, 7 (1) E143-E148
72. Karst, M.; Salim, K.; Burstein, S.; Conrad, I.; Hoy, L.; Schneider, U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neurophatic pain: a randomized controlled trial JAMA, J. Am. Med. Assoc. 2003, 290, 1757-1762
73. CancerNetwork. http://www.cancernetwork.com/nausea-and-vomiting/article/ 10165/109238.
74. 2 receptor J. Med. Chem. 1996, 39, 3875-3877
75. 2 receptor ligands Mini-Rev. Med. Chem. 2005, 5, 641-649
76. 2 receptor Bioorg. Med. Chem. 2006, 14, 2386-2397
77. 2 receptors Bioorg. Med. Chem. 2006, 14, 247-262
78. 1 receptor affinity Pharmacology 2002, 66, 89-99
79. 2 receptor Bioorg. Med. Chem. 1999, 7, 2905-2914
80. Johnson, M. R.; Melvein, L. S., Jr. 2-Hydroxy-4-(substituted)phenyl Cycloalkanes and Derivatives. US4371720, 1983.
81. Howlett, A. C.; Johnson, M. R.; Melvin, L. S.; Milne, G. M. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model Mol. Pharmacol. 1987, 33, 297-302
82. Little, P. J; Compton, D. R.; Johnson, M. R.; Melvin, L. S; Martin, B. R. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice J. Pharmacol. Exp. Ther. 1988, 247, 1046-1051
83. Breivogel, C. S.; Childers, S. R. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protain activation, and adenylyl cyclase inhibition J. Pharmacol. Exp. Ther. 2000, 295, 328-336
84. Yaksh, T. L. Antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat J. Clin. Pharmacol. 1981, 21, 334S-340S
85. Jain, A. K.; Ryan, J. R.; Mcmahon, F. G. Evaluation of intramuscular levonantradol and placebo in acute post-operative pain J. Clin. Pharmacol. 1981, 21, 320S-326S
86. 2 receptor agonists in vitro Br. J. Pharmacol. 2007, 150, 613-623
87. Feldmann, M.; Malfait, A.-M.; Gallily, R.; Mechoulam, R. Use of Cannabinoid as Anti-Inflammatory Agents. WO 199952524, 1999.
88. Mechoulam, R.; Peters, M.; Murillo-Rodriguez, E.; Hanuš, L. O. Cannabidiol-recent advances Chem. Biodiversity 2007, 4, 1678-1692
89. Ligresti, A.; Moriello, A. S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannbidiol on human breast carcinoma J. Pharmacol. Exp. Ther. 2006, 318, 1375-1387
90. Pisanti, S.; Malfitano, A. M.; Grimaldi, C.; Santoro, A.; Gazzerro, P.; Laezza, C.; Bifulco, M. Use of cannabinoid receptor agonists in cancer therpy as palliative and curative agents Best Pract. Res., Clin. Endocrinol. Metab. 2009, 23, 117-131
91. Wade, D.; Makela, P.; House, H.; Bateman, C.; Robson, P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis Mult. Scler. 2006, 12 (5) 639-645
92. Heatlth Canada. Fact Sheet: SATIVEX. http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/notices-avis/conditions/sativex-fs-fd-091289-eng.php.
93. MEDIC. http://www.medic8.com/medicines/Sativex.html.
94. Yacovan, A.; Barjoseph, A.; Meilin, S.; Amseem, S. Orally Effective Cannabinoid Analogs. WO 2006043260, 2006.
95. Pharmos Announces Clinical Data from Phase 2a Trial of Cannabinor for Capsaicin-Induced Pain. http://www.drugs.com/clinical-trials/pharmos-announces- clinical-data-phase-2a-trial-cannabinor-capsaicin-induced-pain-86.html]-fail announcement.
96. Lau, C. K. Cannabinoid Receptor Agonists. US5605906, 1997.
97. 2-selective agonists J. Pharmacol. Exp. Ther. 2002, 301, 679-689
98. 2, a peripheral cannabinoid receptor Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 14228-14233
99. Lambert, D. M.; Fowler, C. J. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic application J. Med. Chem. 2005, 48 (16) 5059-5087
100. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevensson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949
101. De Petrocellis, L.; Bisogno, T.; Davis, J. B.; Pertwee, R. G.; Di Marzo, V. Overlap between the ligand recognition properties of the ananadamide transportor and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsacin-like activity FEBS Lett. 2000, 483, 52-56
102. Lauckner, J. E.; Jensen, J. B.; Chen, H.-Y.; Lu, H.-C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibit M current Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2699-2704
103. 2 receptors in anaesthetized rats Neuropharmacology 2003, 45, 404-411
104. Farquhar-Smith, W. P.; Rice, A. S. C. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder Anesthesiology 2001, 94, 507-513
105. Jaggar, S. I.; Hasnie, F. S.; Sellaturay, S.; Rice, A. S. The anti-hyperalgesic actions of the cannabinoid ananadamide and the putative CB2 receptor agonist palmitoylethnaolamide in visceral and somatic inflammatory pain Pain 1998, 76, 189-199
106. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids Nature 1998, 394, 277-281
107. Richardson, J. D.; Kilo, S.; Hargreaves, K. M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors Pain 1998, 75, 111-119
108. Vivian, J. A.; Kishioka, S.; Butelman, E. R.; Broadbear, J.; Lee, K. O.; Woods, J. H. Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: antagonist effects of SR141716A J. Pharmacol. Exp. Ther. 1998, 286, 697-703
109. Guindon, J.; De Léan, A.; Beaulieu, P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroid anti-inflammatory drug, in acute and inflammatory pain Pain 2006, 121, 85-93
110. Guindon, J.; Beaulieu, P. Antihyperalgesic effects of local injection of anandamide, iibuprofen, rofecoxib and their combinations in a model of neuropathic pain Neurophamacology 2006, 50, 814-823
111. De Petrocellis, L.; Melck, D.; Ueda, N.; Maurellis, S.; Kurahashi, Y.; Yamamoto, S.; Marino, G.; Di Marzo, V. Novel inhibitors of brain neuronal and basophilic anandamide amidohydrolase Biochem. Biophys. Res. Commun. 1997, 231, 82-88
112. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N. E.; Schatz, A. R.; Gopher, A.; Alomog, S.; Martin, B. R.; Compton, D. R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochem. Pharmacol. 1995, 50, 83-90
113. Sugiura, T.; Kondo, S.; Sukawaga, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain Biochem. Biophys. Res. Commun. 1995, 215, 89-97
114. Rouzer, C. A.; Ghebresealasie, K.; Marnett, L. J. Chemical stability of 2-arachidonylglycerol under biological conditions Chem. Phys. Lipids 2002, 119, 69-82
115. Gonsiorek, W.; Lunn, C.; Fan, X.; Narula, S.; Lundell, D.; Hipkin, R. W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide Mol. Pharmacol. 2000, 57, 1045-1050
116. 2 receptors Br. J. Pharmacol. 2000, 150, 693-701
117. Petrosino, S.; Ligresti, A.; Di Marzo, V. Endocannabinoid chemical biology: a tool for the development of novel therapies Curr. Opin. Chem. Biol. 2007, 13, 1-12
118. Dinh, T. P.; Carpenter, D.; Leslie, F. M.; Freund, T. F.; Katona, I.; Sensi, S. L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10819-10824
119. De Petrocellis, L.; Cascio, M. G.; Di Marzo, V. The endocannabinoid system: a general view and latest additions Br. J. Pharmacol. 2004, 141, 765-774
120. 1 receptor Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3662-3665
121. Fezza, F.; Bisogno, T.; Minassi, A.; Appendino, G.; Mechoulam, R.; Di Marzo, V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissue FEBS Lett. 2002, 513, 294-298
122. Laine, K.; Järvinen, K.; Mechoulam, R.; Breuer, A.; Järvinen, T. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid Invest. Ophthalmol. Visual Sci. 2002, 43, 3216-3222
123. 1 receptor J. Pharmacol. Exp. Ther. 2002, 301, 1020-1024
124. 1 receptor Biochem. Pharmacol. 2005, 69, 169-178
125. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Biochem. J. 2000, 351, 817-824
126. Huang, S. M.; Bisogno, T.; Trevisani, M.; Al-Hayani, A.; De Petrocellis, L.; Fezza, F.; Tognetto, M.; Petros, T. J.; Krey, J. F.; Chu, C. J.; Miller, J. D.; Davies, S. N.; Geppetti, P.; Walker, J. M.; Di Marzo, V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptor Proc. Natl. Acad. Sci.U.S.A. 2002, 99, 8400-8405
127. Balvers, M. J.; Verhoeckx, K. C. M.; Witkamp, R. F. Development and validation of a quantitative method for the determination of 12 endocannabinoids and related compounds in human plasma using liquid chromatography-tandem mass spectrometry J. Chromatogr. 2009, 877, 1583-1590
128. Khanolkar, A. D.; Abadji, V.; Lin, S.; Hill, W. A. G.; Taha, G.; Abouzid, K.; Meng, Z.; Fan, P.; Makriyannis, A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand J. Med. Chem. 1996, 39, 4515-4519
129. Abadji, V.; Lin, S.; Taha, G.; Griffin, G.; Stevenson, L. A.; Pertwee, R. G.; Makriyannis, A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability J. Med. Chem. 1994, 37, 1889-1893
130. 1) J. Pharmacol. Exp. Ther. 1999, 289, 1427-1433
131. Bell, M. R.; D'Ambra, T. E.; Kumar, V.; Eissenstat, M. A.; Herrmann, J. L., Jr.; Wetzel, J. R.; Rosi, D.; Philion, R. E.; Daum, S. J.; Hlasta, D. J.; Kullnig, R. K.; Ackerman, J. H.; Haubrich, D. R.; Luttinger, D. A.; Baizman, E. R.; Miller, M. S.; Ward, S. J. Antinociceptive (aminoalkyl)indoles J. Med. Chem. 1991, 34, 1099-1110
132. D'Ambra, T. E.; Estep, K. G.; Bell, M. R.; Eissenstat, M. A.; Josef, K. A.; Ward, S. J.; Haycock, D. A.; Baizman, E. R.; Casiano, F. M.; Beglin, N. C.; Chippari, S. M.; Grego, J. D.; Kullnig, R. K.; Daley, G. T. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor J. Med. Chem. 1992, 35, 124-135
133. Eissenstat, M. A.; Bell, M. R.; D'Ambra, T. E.; Alexander, E. J.; Daum, S. J.; Ackerman, J. H.; Gruett, M. D.; Kumar, V.; Estep, K. G.; Olefirowicz, E. M.; Wetzel, J. R.; Alexander, M. D.; Weaver, J. D., III; Haycock, D. A.; Luttinger, D. A.; Casiano, F. M.; Chippari, S. M.; Kuster, J. E.; Stevenson, J. I.; Ward, S. J. Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics J. Med. Chem. 1995, 38, 3094-3105
134. 9-tetrahydrocannabinol J. Pharmacol. Exp. Ther. 1992, 263 (3) 1118-1126
135. Johanek, L. M.; Simone, D. A. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury Pain 2004, 109, 432-442
136. Johanek, L. M.; Heitmiller, D. R.; Turner, M.; Nadar, N.; Hodges, J.; Simone, D. A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms Pain 2001, 93, 303-315
137. Fox, A.; Kesingland, A.; Gentry, C.; McNair, K.; Patel, S.; Urban, L.; James, I. The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain Pain 2001, 92, 91-100
138. Burgos, E.; Pascual, D.; Martín, M. I.; Goicoechea, C. Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests Eur. J. Pain 2010, 14, 40-48
139. 2 Receptor Agonist Compounds. WO199700860, 1997.
140. 2 receptor? Br. J. Pharmacol. 2006, 149, 145-154
141. Ibrahim, M. M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata, H. P.; Vanderah, T. W.; Lai, J.; Porreca, F.; Makriyannis, A.; Malan, T. P. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (18) 10529-10533
142. 2) selective ligand AM1241 and its resolved enantiomers Br. J. Pharmacol. 2007, 151, 1061-1070
143. Ibrahim, M. M.; Porreca, F.; Lai, J.; Albrecht, P. J.; Rice, F. L.; Khodorova, A.; Davar, G.; Makriyannis, A.; Vanderah, T. W.; Mata, H. P.; Malan, T. P. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (8) 3093-3908
144. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Neuropharmacology 2005, 48 (5) 658-672
145. 2 cannabinoid receptors are implicated in inflammatory pain Pain 2002, 96 (3) 253-260
146. 2-selective agonist, GW-405833 Eur. J. Pharmacol. 2005, 528, 65-72
147. Huffman, J. W.; Padgett, L. W. Recent development in medicinal chemistry of cannabimimetic indoles, pyrroles and indenes Curr. Med. Chem. 2005, 12, 1395-1411
148. Huffman, J. W.; Zengin, G.; Wu, M.-J.; Lu, J.; Hynd, G.; Bushell, K.;
149. Lombard, C.; Nagarkatti, M.; Nagarkatti, P. CB2 cannabinoid receptor agonist, JWH-015 triggers apoptosis in immun cells: potential role for CB2 selective ligands as immunosuppressive agents Clin. Immunol. 2007, 122, 259-270
150. Romero-Sandoval, A.; Eisenach, J. C. Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision Anesthesiology 2007, 106 (4) 787-794
151. Pace, J. M.; Tietje, K.; Dart, M. J.; Meyer, M. D. 3-Cycloalkylcarbonyl Indoles as Cannabinoid Receptor Ligands. WO 2006069196, 2006.
152. 2 cannabinoid receptor activity J. Med. Chem. 2008, 51, 1904-1912
153. 2 receptor agonist exhibiting analgesic activity in rodent pain models Br. J. Pharmacol. 2008, 153, 390-401
154. 2 cannabinoid receptor activity J. Med. Chem. 2010, 53, 295-315
155. Hynes, J., Jr.; Leftheris, K.; Wu, H.; Pandit, C.; Chen, P.; Norris, D. J.; Chen, B.-C.; Zhao, R.; Kiener, P. A.; Chen, X.; Turk, L. A.; Patil-Koota, V.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W. C-3-Amido-indole cannabinoid receptor modulators Bioorg. Med. Chem. Lett. 2002, 12, 2399-2402
156. Wrobleski, S. T.; Chen, P.; Hynes, J., Jr.; Lin, S.; Norris, D. J.; Pandit, C. R.; Spergel, S.; Wu, H.; Tokarski, J. S.; Chen, X.; Gillooly, K. M.; Kiener, P. A.; McIntyre, K. W.; Patil-Koota, V.; Shuster, D. J.; Turk, L. A.; Yang, G.; Leftheris, K. Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties J. Med. Chem. 2003, 46, 2110-2116
157. 2 Agonists and Method. WO 2009015169, 2009.
158. Cheng, Y.-X.; Tomaszewski, M.; Walpole, C.; Yang, H. Novel Compounds. WO 2002085866, 2002.
159. 2 agonists Bioorg. Med. Chem. Lett. 2008, 18, 3695-3700
160. Liu, Z.; Yang, H.; Ducharme, J.; Page, D.; Wei, Z.-Y.; Tremblay, M.; Srivastava, S.; Dolaine, R.; Milburn, C. J.; Lessard, E.; Morin, P. E.; St-Onge, S.; Payza, K.; Walpole, C. Presented at the 31st National Medicinal Chemistry Symposium, Pittsburgh, PA, June 2008; Abstract 240.
161. Kato, T.; Kon-I, K.; Yuki, Y.; Ando, K. Sulfonyl Benzimidazole Derivatives. WO 2007102059, 2007.
162. Kon-I, K.; Matsumizu, M.; Shima, A. Sulfonyl Benzimidazole Derivatives. WO 2006048754, 2006.
163. 2 agonists Bioorg. Med. Chem. Lett. 2011, 21, 4284-4287
164. Ando, K.; Iwata, Y. N-Substituted Saturated Heterocyclic Sulfone Compounds with CB2 Receptor Agonistic Activity. WO 2010084767, 2010.
165. RaQualia. http://www.raqualia.com.
166. Gijsen, H. J. M.; De Cleyn, M. A. J.; Surkyn, M.; Verbist, B. M. P. Benzimidazole Cannabinoid Agonists Bearing a Substituted Heterocyclic Group. WO 20008003665, 2008.
167. 2 agonists Bioorg. Med. Chem. Lett. 2008, 18, 2574-2579
168. Gijsen, H. J. M.; De Cleyn, M. A. J.; Surkyn, M. Benzimidazole Cannabinoid Agonists. WO2008119694, 2008.
169. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thomson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficacy (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409
170. Omura, H.; Kawai, M.; Shima, A.; Iwata, Y.; Ito, F.; Masuda, T.; Ohta, A.; Makita, N.; Omoto, K.; Sugimoto, H.; Kikuchi, A.; Iwata, H.; Ando, K. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives Bioorg. Med. Chem. Lett. 2008, 18, 3310-3314
171. 2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity J. Pharmacol. Sci. 2008, 106, 219-224
172. 2 Receptor Modulators, Useful in the Treatment of Pain, Respiratory and Non-Respiratory Diseases. WO 2008085302, 2008.
173. Trotter, B. W.; Nanda, K. K.; Burgey, C. S.; Potteiger, C. M.; Deng, J. Z.; Green, A. I.; Hartnett, J. C.; Kett, N. R.; Wu, Z.; Henze, D. A.; Penna, K. D.; Desai, R.; Leitl, M. D.; Lemaire, W.; White, R. B.; Yeh, S.; Urban, M. O.; Kane, S. A.; Hartman, G. D.; Bilodeau, M. T. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy Bioorg. Med. Chem. Lett. 2011, 21, 2354-2358
174. 2 Receptor Ligands for the Treatment of Pain. WO 2009025785, 2009.
175. Beckett, R. P.; Foster, R.; Henault, C.; Ralbovsky, J. L.; Gauss, C. M.; Gustafson, G. R.; Luo, Z.; Campbell, A.-M.; Shelekhin, T. E. Substituted Imidazoheterocycles. WO 2008157751, 2008.
176. O'Connor, S. J.; Newcom, J. S.; Ralbovsky, J. L.; Gustafson, G. R.; Beckett, R. P.; Luo, R. X. Substituted Imidazoheterocycle Derivatives. WO 2010068520, 2010.
177. Barth, F.; Congy, C.; Rinaldi-Carmora, M.; Vernhet, C. Condensed Pyrazole Derivatives, Preparation Method Thereof and Therapeutic Use of Same. WO 2006030124, 2006.
178. Muthuppalanippan, M.; Balasubramanian, G.; Gullapalli, S.; Joshi, N. K.; Narayanan, S. Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process for Their Preparation. WO 2006129178, 2006.
179. Muthuppalanippan, M.; Sukeerthi, K.; Balasubramanian, G.; Gullapalli, S.; Joshi, N. K.; Narayanan, S.; Karnik, P. V. Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process for Their Preparation. WO 2008053341, 2008.
180. Glenmark's Molecule for Neuropathic Pain, Osteoarthritis-GRC 10693, Successfully Completes Phase I Trials. http://www.evaluatepharma.com/Universal/ View.aspx?type=Story&id=183092.
181. 2 Receptor Agonist with Potential Anti-Hyperalgesic Effects. Presented at the 36th Annual Meeting of the Society for Neuroscience, Atlanta, GA, Oct 14, 2006.
182. Liotta, F.; Xia, M.; Wachter, M. P.; Beers, S. A. Tetrahydro-cyclopentyl Pyrazole Cannabinoid Modulators. WO 2007035945, 2007.
183. Liotta, F.; Wachter, M. P.; Xia, M. Tetrahydro-indazolyl Cannabinoid Modulators. WO 2007038045, 2007.
184. Xia, M.; Lu, H.; Liotta, F.; Pan, M.; Wachter, M. P.; Macielag, M. J. Hexahydro-cycloheptapyrazole Cannabinoid Modulators. WO 2008115705, 2008.
185. Liotta, F. Hexahydro-cyclooctyl Pyrazole Cannabinoid Modulators. WO 2007044215, 2007.
186. Eatherton, A. J.; Giblin, G. M. P.; Mitchell, W. L.; Naylor, A.; Page, L. W.; Swarbrick, M.; Sweeting, J. A. Imidazopyridine Derivatives as Cannabinoid Receptor Ligands. WO 2007017237, 2007.
187. Eatherton, A. J.; Giblin, G. M. P.; Mitchell, W. L. Compounds. WO 2007088168, 2007.
188. Eatherton, A. J.; Giblin, G. M. P.; Jandu, K. S.; Johnson, M. R.; Mitchell, W. L.; Naylor, A.; Sweeting, J. A. Compounds. WO 2007017264, 2007.
189. 2 agonist for the treatment of chronic pain J. Med. Chem. 2009, 52, 5785-5788
190. Astles, P. C.; Guidetti, R.; Tidwell, M. W.; Hollinshead, S. P. Purine Compounds. US 20100160288, 2010.
191. 2 agonists. WO2011123482, 2011.
192. Astles, P. C.; Guidetti, R.; Tidwell, M. W.; Sanderson, A. J.; Hollinshead, S. P. Purine Compounds. WO2011123372, 2011.
193. 2 agonists Bioorg. Med. Chem. Lett. 2012, 22, 4962-4966
194. 2 Agonist, LY2828360 Is Efficacious in Chronic Pain Models. Presented at the 2012 Neurosicence Meeting Planner, New Orleans, LA, October 2012.
195. A Study of LY2828360 in Patients with Osteoarthritic Knee Pain. http://clinicaltrials.gov/show/NCT01319929.
196. 2 selective agonists Bioorg. Med. Chem. Lett. 2007, 17, 6505-6510
197. Manera, C.; Saccomanni, G.; Adinolfi, B.; Benetti, V.; Ligresti, A.; Cascio, M. G.; Tuccinardi, T.; Lucchesi, V.; Martinelli, A.; Nieri, P.; Masini, E.; Di Marzo, V.; Ferrarini, P. L. Rational design, synthesis and pharmacological properties of new 1,8-naphthyridin-2(1 H)-on-3-carboxamide derivatives as highly selective cannabinoid-2-receptor agents J. Med. Chem. 2009, 52, 3644-3651
198. Pasquini, S.; Botta, L.; Semeraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigation on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo J. Med. Chem. 2008, 51, 5075-5084
199. Pasquini, S.; De Rosa, M.; Pedani, V.; Mugnaini, C.; Guida, F.; Luongo, L.; De Chiaro, M.; Maione, S.; Dragoni, S.; Frosini, M.; Ligresti, A.; Di Marzo, V.; Corelli, F. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice J. Med. Chem. 2011, 54, 5444-5453
200. Pasquini, S.; Ligresti, A.; Mugnaini, C.; Semeraro, T.; Cicione, L.; De Rosa, M.; Guida, F.; Luongo, L.; De Chiaro, M.; Cascio, M. G.; Bolognini, D.; Marini, P.; Pertwee, R.; Maione, S.; Di Marzo, V.; Corelli, F. Investigation on the 4-quinolone-3-carboxylic acid motif. 3. Synthesis, structure-affinity relationships, and pharmacological characterization of 6-substituted 4-quinolone-3-carboxamides as highly selective cannabinoid-2-receptor ligands J. Med. Chem. 2010, 53, 5915-5928
201. 2 cannabinoid receptor partial agonists J. Med. Chem. 2013, 56, 1098-1112
202. Baraldi, P. G.; Saponaro, G.; Moorman, A. R.; Romagnoli, R.; Preti, D.; Baraldi, S.; Ruggiero, E.; Varani, K.; Targa, M.; Vincenzi, F.; Borea, P. A.; Tabrizi, M. A. 7-Oxo-[1.4]oxazino[2,3,4- ij ]quinolone-6-carboxamides as selective CB2 cannabinoid receptor ligands: structure investigations around a novel class of full agonists J. Med. Chem. 2012, 55, 6608-6623
203. Gustafson, G. R.; Beckett, R. P. Tetrahydroquinolinones, Tetrahydronaphthyridones and Derivatives Thereof. WO 2008079316, 2008.
204. Newcom, J. S.; Gauss, C. M.; Gustafson, G. R. Benzo-Fused Heterocycles. WO 2009035997, 2009.
205. Newcom, J. S.; O'Connor, S. J.; Gustafson, G. R. Substituted Pyridoxazines. WO 2009120660, 2009.
206. 2 Receptor. WO 2007039220, 2007.
207. Gahman, T. C.; Thomas, D. J.; Lang, H.; Massari, M. E. Aminoquinazoline Cannabinoid Receptor Modulators for Treatment of Disease. WO 2008157500, 2008.
208. Manley, P. J.; Zartman, A.; Paone, D. V.; Burgey, C. S.; Henze, D. A.; Penna, K. D.; Desai, R.; Leitl, M. D.; Lemaire, W.; White, R. B.; Yeh, S.; Urban, M. O.; Kane, S. A.; Hartman, G. D.; Bilodeau, M. T.; Trotter, B. W. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia Bioorg. Med. Chem. Lett. 2011, 21, 2359-2364
209. 2 Cannabinoid Receptor Ligands. WO 2008028093, 2008.
210. 2 Cannabinoid Receptor Ligands. WO 2008028094, 2008.
211. Carroll, W. A.; Nelson, D. W.; Perez-Medrano, A. Novel Compounds as Cannabinoid Receptor Ligands. WO 2009009550, 2009.
212. Nelson, D. W.; Gallagher, M. E.; Ryther, K. Presented at the 31st National Medicinal Chemistry Symposium, Pittsburgh, PA, June 2008; Abstract 220.
213. Diaz, P.; Xu, J.; Astruc-Diaz, F.; Pan, H.-M.; Brown, D. L.; Naguib, M. Design and synthesis of a novel series of N -alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain J. Med. Chem. 2008, 51, 4932-4947
214. 2 receptors that prevents allodynia in rat neuropathic pain models Br. J. Pharmacol. 2008, 155, 1104-1116
215. Sprott, K.; Rohde, J.; Nakai, T.; Peng, B.; Talley, J. J. CB Receptor Agonists. WO 2011006066, 2011.
216. Rohde, J.; Kim, C.; Nakai, T. Cannabinoid Receptor Agonists. WO 2011100324, 2011.
217. Rohde, J.; Peng, B.; Nakai, T.; Sprott, K.; Mermerian, A.; Schairer, W. C. Cannabinoid Agonists. WO 2011100359, 2011.
218. 2 Modulators. WO 2004018433, 2004.
219. Eatherton, A. J.; Giblin, G. M. P.; Green, R. H.; Mitchell, W. L.; Naylor, A.; Rawlings, D. A.; Slingsby, B. P.; Whittington, A. R. Pyrimidine Compounds. WO 2004018434, 2004.
220. 2 Receptor Modulators. WO 2004029027, 2004.
221. 2 Receptor Modulators. WO 2005080342, 2005.
222. Worsley, M. A.; Clayton, N. M.; Goldsmith, P.; Giblin, G.; Wilson, A.; Boissonade, F. M. The Effect of CB2 Agonist GW833972A on Trigeminal Fos Expression. Presented at the IADR Pan European Federation 2006, Sep 13-16, 2006; No. 0454 Neuroscience Poster Session.
223. 2 Modulators and PDE4 Inhibitors for Use in Medicine. WO 2005074939, 2005.
224. 2 receptor agonist for the treatment of inflammatory pain J. Med. Chem. 2007, 50, 2597-2600
225. Dental Pain 3rd Molar Tooth Extraction GW842166. http://clinicaltrials. gov/ct2/show/NCT00444769?term=GW842166X&rank=4.
226. A Study of GW842166 in Adults with Osteoarthritis Pain. http://clinicaltrials.gov/ct2/show/NCT00447486.
227. 2 agonists for analgesia Bioorg. Med. Chem. Lett. 2009, 19, 259-263
228. Matsushima, Y.; Kubota, H.; Hamaguchi, H.; Okamoto, Y.; Hondo, T.; Nishigaki, F. Pyrimidine Compound. WO 2010113834, 2010.
229. 2 agonists: synthesis and investigation of structure-activity relationships Bioorg. Med. Chem. Lett. 2009, 19, 6578-6581
230. 2 agonists for the treatment of inflammatory pain Bioorg. Med. Chem. Lett. 2010, 20, 465-468
231. Gleave, R.; Mitchell, W. L.; Page, L. W.; Swarbrick, M. Pyridazine Derivatives with Anti-Inflammatory Activity. WO 2007022937, 2007.
232. Gleave, R.; Mitchell, W. L.; Page, L. W.; Swarbrick, M.; Walters, D. J. Compounds. WO 2007022938, 2007.
233. 2 selective agonists Bioorg. Med. Chem. Lett. 2009, 19, 1604-1609
234. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged molecules for protein binding identified from NMR-based screening J. Med. Chem. 2000, 43, 3443-3447
235. 2 Receptor. WO 200848914, 2008.
236. Van Der Stelt, M.; Cals, J. M. G. B. 1-(Biphenyl-4-ylmethyl) imidazolidine-2,4-dione Derivatives and Their Use as CB2 Receptor Agonists. WO 2010063721, 2010.
237. Van Der Stelt, M.; Cals, J.; Josten, S. B.; Cottney, J.; Van Der Doelen, A.; Hermkens, M.; De Kimpe, V.; King, A.; Klomp, J.; Oosterom, J.; Rooij, I. P.-D.; De Roos, J.; Van Tilborg, M.; Boyce, S.; Baker, J. Discovery and optimization of 1-(4-(pyridine-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists J. Med. Chem. 2011, 54, 7350-7362
238. 2 cannabinoid receptor ligands Bioorg. Med. Chem. Lett. 2008, 18, 2830-2835
239. 2 selectivity Bioorg. Med. Chem. Lett. 2008, 18, 1725-1729
240. 2 Receptor. WO 2008098025, 2008.
241. 2 Receptor Agonists. Presented at the Molecular Medicine Tri-Conference, San Francisco, CA, March 2008.
242. 2 selective sulfamoyl benzamides: optimization of the amide functionality Bioorg. Med. Chem. Lett. 2009, 19, 309-313
243. 2 agonists with improved in vitro metabolic stability Bioorg. Med. Chem. Lett. 2010, 20, 387-391
244. 2 agonists Bioorg. Med. Chem. Lett. 2009, 19, 5004-5008
245. 2 cannabinoid receptor agonists Bioorg. Med. Chem. Lett. 2009, 19, 5931-5935
246. 2 cannabinoid receptor agonists Bioorg. Med. Chem. Lett. 2007, 17, 5133-5135
247. 2 cannabinoid receptor agonists with good oral bioavailability Bioorg. Med. Chem. Lett. 2007, 17, 6299-6304
248. 2 cannabinoid receptor agonists with an analgesic action Bioorg. Med. Chem. 2008, 16, 1111-1124
249. Dart, M. J.; Carroll, W. A.; Florjancic, A. S.; Frost, J. M.; Gallagher, M. E.; Li, T.; Nelson, D. W.; Patel, M. V.; Peddi, S.; Perez-Medrano, A.; Ryther, K. B.; Tietje, K. R.; Kolasa, T. Novel Compound as Cannabinoid Receptor Ligands and Uses Thereof. WO 2007140385, 2007.
250. Yao, B. B.; Hsieh, G.; Daza, A. V.; Fan, Y.; Grayson, G. K.; Garrison, T. R.; El Kouhen, O.; Hooker, B. A.; Pai, M.; Wensink, E. J.; Salyers, A. K.; Chandran, P.; Zhu, C. Z.; Zhong, C.; Ryther, K.; Gallagher, M. E.; Chin, C.-L.; Tovcimak, A. E.; Hradil, V. P.; Fox, G. B.; Dart, M. J.; Honore, P.; Meyer, M. D. Characterization of a cannabinoid CB2 receptor-selective agonist, A-836339 [2,2,3,3-tetramethyl-cyclopropanecarboxylic acid [3-(2-methoxy-ethyl)-4,5- dimethyl-3 H -thiazol-(2 Z)-ylidene]-amide], using in vitro pharmacological assays, in vivo pain models, and pharmacological magnetic resonance imaging J. Pharmacol. Exp. Ther. 2009, 328, 141-151
251. Perezmedrano, A.; Li, T.; Peddi, S.; Carroll, W. A.; Dart, M. J. Novel Compounds as Cannabinoid Receptor Ligands and Uses Thereof. WO 2008079687, 2008.
252. Carroll, W. A.; Dart, M. J.; Kolasa, T.; Meyer, M. D.; Patel, M. V.; Wang, X. Novel Compounds as Cannabinoid Receptor Ligands. WO 2008063781, 2008.
253. Carroll, W. A.; Dart, M. J.; Frost, J. M.; Latshaw, S. P.; Kolasa, T.; Li, T.; Peddi, S.; Liu, B.; Perez-Medrano, A.; Patel, M.; Wang, X.; Nelson, D. W. Novel Compounds as Cannabinoid Receptor Ligands. WO 2010033543, 2010.
254. Carroll, W. A.; Dart, M. J.; Frost, J. M.; Kolasa, T.; Li, T.; Liu, B.; Perez-Medrano, A.; Patel, M.; Wang, X.; Peddi, S. Novel Compounds as Cannabinoid Receptor Ligands. WO 2010028338, 2010.
255. Wang, X.; Frost, J. M.; Dart, M. J.; Liu, B. Compounds as Cannabinoid Receptor Ligands. WO 2010111573, 2010.
256. 2 Bioorg. Med. Chem. Lett. 2008, 18, 4267-4274
257. 2) agonists J. Med. Chem. 2008, 51, 5019-5034
258. Yang, S.-W.; Smotryski, J.; Matasi, J.; Ho, G.; Tulshian, D.; Greenlee, W. J.; Brusa, R.; Beltramo, M.; Cox, K. Structure-activity relationships of 2,4-diphenyl-1 H -imidazole analogs as CB2 receptor agonists for the treatment of chronic pain Bioorg. Med. Chem. Lett. 2011, 21, 182-185
259. 2: synthesis, SAR, and pharmacokinetic properties Bioorg. Med. Chem. Lett. 2009, 19, 31-35
260. 2 Receptor. WO 2008039645, 2008.
261. Bartolozzi, A.; Riether, D.; Zindell, R.; Amouzegh, P.; Blumire, N. J.; Ermann, M.; Scott, R. J.; Mushi, I. Compounds Which Selectively Modulate the CB2 Receptor. WO 2011037795, 2011.
262. Bartolozzi, A.; Berry, A.; Hickey, E. R.; Ostermeier, M.; Riether, D.; Sauer, A.; Thomson, D. S.; Wu, L.; Zindell, R. M.; Amouzegh, P.; Blumire, N. J.; East, S. P.; Ermann, M.; Khor, S.; Mushi, I. Compounds Which Selectively Modulate the CB2 Receptor. WO 2010036630, 2010.
263. Bartolozzi, A.; Hickey, E. R.; Riether, D.; Wu, L.; Zindell, R.; East, S. P.; Ermann, M. Compounds Which Selectively Modulate the CB2 Receptor. WO 2010036631, 2010.
264. Berry, A.; Riether, D.; Zindeli, R.; Blumire, N. J. Compounds Which Modulate the CB2 Receptor. WO 2009061652, 2009.
265. Bartolozzi, A.; Hickey, E. R.; Riether, D.; Wu, L.; Zindell, R.; Blumire, N.; Ermann, M.; Glenn, E. T.; Khor, S.; Zawadzki, P. Compounds Which Selectively Modulate the CB2 Receptor. WO 2010147792, 2010.
266. 2 Receptor. WO 2008064054, 2008.
267. Cirilio, P. F.; Hickey, E. R.; Riether, D.; Wu, L.; Zindell, R.; Amouzegh, P.; Ermann, M.; Walker, E. Diazepane Compounds Which Modulate the CB2 Receptors. WO 2009055357, 2009.
268. Riether, D.; Wu, L.; Cirillo, P. F.; Berry, A.; Walker, E. R.; Ermann, M.; Noya-Marino, B.; Jenkins, J. E.; Albaugh, D.; Albrecht, C.; Fisher, M.; Gemkow, M. J.; Grbic, H.; Löbbe, S.; Möller, C.; O'Shea, K.; Sauer, A.; Shih, D.-T.; Thomson, D. S. 1,4-Diazepane compounds as potent and selective CB2 agonists: optimization of metabolic stability Bioorg. Med. Chem. Lett. 2011, 21, 2011-2016
269. Zindell, R.; Walker, E. R.; Scott, J.; Amouzegh, P.; Wu, L.; Ermann, M.; Thomson, D.; Fisher, M. B.; Fullenwider, C. L.; Grbic, H.; Kaplita, P.; Linehan, B.; Patel, M.; Patel, M.; Löbbe, S.; Block, S.; Albrecht, C.; Gemkow, M. J.; Shih, D.-T.; Rirther, D. Aryl 1,4-diazepane compounds as potent and selective CB2 agonists: optimization of drug-like properties and target independent parameters Bioorg. Med. Chem. Lett. 2011, 21, 4276-4280
270. Hickey, E. R.; Riether, D.; Thomson, D. S.; Wu, L.; Zindell, R. M. Azetidine 2-Carboxamide Derivatives Which Modulate the CB2 Receptor. WO 2010147791, 2010.
271. Berry, A.; Betageri, R.; Riether, D.; Hickey, E. R.; Wu, L.; Zindell, R. M.; Khor, S. Pyrrolidine Compounds Which Modulate the CB2 Receptor. WO 2010077836, 2010.
272. Bartolozzi, A.; Berry, A.; Cirillo, P. F.; Hickey, E. R.; Riether, D.; Wu, L.; Zindell, R. M. Heterocyclic Compounds Which Modulate the CB2 Receptor. WO 2010096371, 2010.
273. 2 receptor selective compounds Bioorg. Med. Chem. Lett. 2007, 17, 4030-4034
274. Kai, H.; Tomida, M. 2-Azolylimino-1,3-thiazine Derivative. WO 2006080287, 2006.
275. Kai, H.; Morioka, Y.; Tomida, M.; Takahashi, T.; Hattori, M.; Hanasaki, K.; Koike, K.; Chiba, H.; Shinohara, S.; Kanemasa, T.; Iwamoto, Y.; Takahashi, K.; Yamaguchi, Y.; Baba, T.; Yoshikawa, T.; Takenaka, H. 2-Arylimino-5,6- dihydro-4 H -1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds Bioorg. Med. Chem. Lett. 2007, 17, 3925-3929
276. Kai, H.; Okamoto, K. 2-Substituted Imino-1,3-oxazine Derivative. WO 2006080284, 2006.
277. A Phase Ib/IIa, Double-Blind, Randomized Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects with Atopic Dermatitis. http://clinicaltrials.gov/ct2/show/NCT00697710.
278. Odan, M.; Ishizuka, N.; Hiramatsu, Y.; Inagaki, M.; Hashizume, H.; Fujii, Y.; Mitsumori, S.; Morioka, Y.; Soga, M.; Deguchi, M.; Yasui, K.; Arimura, A. Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent Bioorg. Med. Chem. Lett. 2012, 22, 2803-2806
279. Chen, J.; Pettit, S. N.; Fliri, H. G. Pyridazine Derivatives Useful as Cannabinoid-2 Agonists. WO 2011097553, 2011.
280. 2 cannabinoid receptors Bioorg. Med. Chem. 2003, 11, 251-263
281. 2 cannabinoid ligand 1-(2′,4′- dichlorophenyl)-6-methyl- N -piperidin-1-yl-1,4-dihydroindeno[1,2- c ]pyrazole-3-carboxamide J. Med. Chem. 2006, 49, 7502-7512
282. 2 agonist, alleviates neuropathic pain through frunctional microglial changes in mice Neurobiol. Dis. 2010, 37, 177-185
283. 2) in rodents and primates Br. J. Pharmacol. 2007, 151, 1262-1271
284. Ralbovsky, J. L; Beckett, P. R. Bridged Phenanthridines. WO 2008109007, 2008.
285. 2 receptor agonists Bioorg. Med. Chem. Lett. 2007, 17, 6183-6187
286. Dollings, P. J.; Donnell, A. F.; Gilbert, A. M.; Zhang, M.; Harrison, B. L.; Stanton, C. J., III; O'Neil, S. V.; Havran, L. M.; Chong, D. C. Substituted Oxindole CB2 Agonists for Pain Treatment. WO 2010077839, 2010.
287. Zhang, M.; Harrison, B. L.; Stanton, C. J., III; Havran, L. M.; Chong, D. C.; Childers, W. E.; O'Neil, S. V. Substituted Oxindole CB2 Agonists. WO 2010090680, 2010.
288. Jones, R. M.; Han, S.; Thoresen, L.; Jung, J.-K.; Strah-Pleynet, S.; Zhu, X.; Xiong, Y.; Yue, D. Cannabinoid Receptor Modulators. WO 2011025541, 2011.
289. JBC Therapeutics. http://jbtherapeutics.com/?page-id=107.
290. A Comparative Study of KHK6188. http://clinicaltrials.gov/ct2/show/ NCT01544296.
291. Advancing Abbott's Long-Term Strategy. http://media.corporate-ir.net/ media-files/irol/94/94004/presentations/Abbott-Investor-Day-2011r.pdf.
292. Kalliomaki, J.; Segerdahl, M.; Webster, L.; Reimfelt, A.; Huizar, K.; Annas, P.; Karlsten, R.; Quiding, H. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal Scand. J. Pain 2013, 4, 17-22
293. Cara Therapeutics. http://www.caratherapeutics.com/cr701.shtml.
294. Arena Pharmaceuticals, Inc. http://www.arenapharm.com.
295. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass Proc Natl Acad Sci U. S. A 2006, 103, 696-701
296. Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; Morieux, C.; Kornak, U.; Essig, J.; Erxlebe, E.; Bab, I.; Kubisch, C.; de Vernejoul, M. C.; Zimmer, A. Cannabinoid receptor type 2 gene is associated with human osteoporosis Hum. Mol. Genet. 2005, 14, 3389-3396
297. Idris, A. I.; van 't Hof, R. J.; Greig, I. R.; Ridge, S. A.; Baker, D.; Ross, R. A.; Ralston, S. H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors Nat. Med. 2005, 11, 774-779
298. Lunn, C. A.; Fine, J.; Rojas-Triana, A.; Jackson, J. V.; Lavey, B.; Kozlowski, J. A.; Hipkin, R. W.; Lundell, D. J.; Bober, L. Cannabinoid CB(2)-selective inverse agonist protects against antigen-induced bone loss Immunopharmacol. Immunotoxicol. 2007, 29, 387-401
299. Shankar, B. B.; Lavey, B. J.; Zhou, G.; Spitler, J. A.; Tong, L.; Rizvi, R.; Yang, D. Y.; Wolin, R.; Kozlowski, J. A.; Shih, N. Y.; Wu, J.; Hipkin, R. W.; Gonsiorek, W.; Lunn, C. A. Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies Bioorg. Med. Chem. Lett. 2005, 15, 4417-4420
300. Sospedra, M.; Martin, R. Immunology of multiple sclerosis Annu. Rev. Immunol. 2005, 23, 683-747
301. Ponomarev, E. D.; Shriver, L. P.; Maresz, K.; Dittel, B. N. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity J. Neurosci. Res. 2005, 81, 374-389
302. Cabral, G. A.; Marciano-Cabral, F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance J. Leukocyte Biol. 2005, 78, 1192-1197
303. Maresz, K.; Carrier, E. J.; Ponomarev, E. D.; Hillard, C. J.; Dittel, B. N. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli J. Neurochem. 2005, 95, 437-445
304. Ehrhart, J.; Obregon, D.; Mori, T.; Hou, H.; Sun, N.; Bai, Y.; Klein, T.; Fernandez, F.; Tan, J.; Shytle, R. D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation J. Neuroinflammation 2005, 2, 29
305. Correa, F.; Docagne, F.; Mestre, L.; Clemente, D.; Hernangomez, M.; Loria, F.; Guaza, C. A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells Biochem. Pharmacol. 2009, 77, 86-100
306. Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzman, M.; Galve-Roperh, I. Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation FASEB J. 2006, 20, 2405-2407
307. Maresz, K.; Pryce, G.; Ponomarev, E. D.; Marsicano, G.; Croxford, J. L.; Shriver, L. P.; Ledent, C.; Cheng, X.; Carrier, E. J.; Mann, M. K.; Giovannoni, G.; Pertwee, R. G.; Yamamura, T.; Buckley, N. E.; Hillard, C. J.; Lutz, B.; Baker, D.; Dittel, B. N. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells Nat. Med. 2007, 13, 492-497
308. Palazuelos, J.; Davoust, N.; Julien, B.; Hatterer, E.; Aguado, T.; Mechoulam, R.; Benito, C.; Romero, J.; Silva, A.; Guzman, M.; Nataf, S.; Galve-Roperh, I. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis J. Biol. Chem. 2008, 283, 13320-13329
309. Ni, X.; Geller, E. B.; Eppihimer, M. J.; Eisenstein, T. K.; Adler, M. W.; Tuma, R. F. WIN 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model Mult. Scler. 2004, 10, 158-164
310. Croxford, J. L.; Miller, S. D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212 J. Clin. Invest. 2003, 111, 1231-1240
311. Sanchez, A. J.; Gonzalez-Perez, P.; Galve-Roperh, I.; Garcia-Merino, A. R -(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3- de ]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor Biochem. Pharmacol. 2006, 72, 1697-1706
312. Revalo-Martin, A.; Vela, J. M.; Molina-Holgado, E.; Borrell, J.; Guaza, C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis J. Neurosci. 2003, 23, 2511-2516
313. Lunn, C. A.; Reich, E. P.; Bober, L. Targeting the CB2 receptor for immune modulation Expert Opin. Ther. Targets 2006, 10, 653-663
314. Lunn, C. A.; Reich, E. P.; Fine, J. S.; Lavey, B.; Kozlowski, J. A.; Hipkin, R. W.; Lundell, D. J.; Bober, L. Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists Br. J. Pharmacol. 2008, 153, 226-239
315. Grabbe, S.; Schwarz, T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity Immunol. Today 1998, 19, 37-44
316. Karsak, M.; Gaffal, E.; Date, R.; Wang-Eckhardt, L.; Rehnelt, J.; Petrosino, S.; Starowicz, K.; Steuder, R.; Schlicker, E.; Cravatt, B.; Mechoulam, R.; Buettner, R.; Werner, S.; Di Marzo, V.; Tuting, T.; Zimmer, A. Attenuation of allergic contact dermatitis through the endocannabinoid system Science 2007, 316, 1494-1497
317. Ueda, Y.; Miyagawa, N.; Wakitani, K. Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice Life Sci. 2007, 80, 414-419
318. Maekawa, T.; Nojima, H.; Kuraishi, Y.; Aisaka, K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis Eur. J. Pharmacol. 2006, 542, 179-183
319. Pacher, P.; Hasko, G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning Br. J. Pharmacol. 2008, 153, 252-262
320. Hillard, C. J. Role of cannabinoids and endocannabinoids in cerebral ischemia Curr. Pharm. Des. 2008, 14, 2347-2361
321. Batkai, S.; Osei-Hyiaman, D.; Pan, H.; El-Assal, O.; Rajesh, M.; Mukhopadhyay, P.; Hong, F.; Harvey-White, J.; Jafri, A.; Hasko, G.; Huffman, J. W.; Gao, B.; Kunos, G.; Pacher, P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury FASEB J. 2007, 21, 1788-1800
322. Defer, N.; Wan, J.; Souktani, R.; Escoubet, B.; Perier, M.; Caramelle, P.; Manin, S.; Deveaux, V.; Bourin, M. C.; Zimmer, A.; Lotersztajn, S.; Pecker, F.; Pavoine, C. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy FASEB J. 2009, 23, 2120-2130
323. Zhang, M.; Martin, B. R.; Adler, M. W.; Razdan, R. K.; Jallo, J. I.; Tuma, R. F. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model J. Cereb. Blood Flow Metab. 2007, 27, 1387-1396
324. Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Batkai, S.; Osei-Hyiaman, D.; Hasko, G.; Liaudet, L.; Gao, B.; Pacher, P. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis J. Leukocyte Biol. 2007, 82, 1382-1389
325. Montecucco, F.; Lenglet, S.; Braunersreuther, V.; Burger, F.; Pelli, G.; Bertolotto, M.; Mach, F.; Steffens, S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion J. Mol. Cell. Cardiol. 2009, 46, 612-620
326. Zhang, M.; Martin, B. R.; Adler, M. W.; Razdan, R. K.; Ganea, D.; Tuma, R. F. Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury Neuroscience 2008, 152, 753-760
327. Ross, R. Atherosclerosis is an inflammatory disease Am. Heart J. 1999, 138, S419-S420
328. Ross, R. Cell biology of atherosclerosis Annu. Rev. Physiol. 1995, 57, 791-804
329. Steffens, S.; Veillard, N. R.; Arnaud, C.; Pelli, G.; Burger, F.; Staub, C.; Karsak, M.; Zimmer, A.; Frossard, J. L.; Mach, F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice Nature 2005, 434, 782-786
330. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease N. Engl. J. Med. 2005, 352, 1685-1695
331. Hansson, G. K.; Libby, P. The immune response in atherosclerosis: a double-edged sword Nat. Rev. Immunol. 2006, 6, 508-519
332. Montecucco, F.; Burger, F.; Mach, F.; Steffens, S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways Am. J. Physiol.: Heart Circ. Physiol. 2008, 294, H1145-H1155
333. Arai, S.; Shelton, J. M.; Chen, M.; Bradley, M. N.; Castrillo, A.; Bookout, A. L.; Mak, P. A.; Edwards, P. A.; Mangelsdorf, D. J.; Tontonoz, P.; Miyazaki, T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development Cell Metab. 2005, 1, 201-213
334. Liu, J.; Thewke, D. P.; Su, Y. R.; Linton, M. F.; Fazio, S.; Sinensky, M. S. Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice Arterioscler., Thromb., Vasc. Biol. 2005, 25, 174-179
335. Libby, P.; Geng, Y. J.; Aikawa, M.; Schoenbeck, U.; Mach, F.; Clinton, S. K.; Sukhova, G. K.; Lee, R. T. Macrophages and atherosclerotic plaque stability Curr. Opin. Lipidol. 1996, 7, 330-335
336. Kockx, M. M.; Herman, A. G. Apoptosis in atherosclerosis: beneficial or detrimental? Cardiovasc. Res. 2000, 45, 736-746
337. Freeman-Anderson, N. E.; Pickle, T. G.; Netherland, C. D.; Bales, A.; Buckley, N. E.; Thewke, D. P. Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis J. Lipid Res. 2008, 49, 2338-2346
338. Barbara, G.; De, G. R.; Stanghellini, V.; Cremon, C.; Corinaldesi, R. A role for inflammation in irritable bowel syndrome? Gut 2002, 51 (Suppl. 1) i41-i44
339. Mayer, E. A.; Collins, S. M. Evolving pathophysiologic models of functional gastrointestinal disorders Gastroenterology 2002, 122, 2032-2048
340. Rousseaux, C.; Thuru, X.; Gelot, A.; Barnich, N.; Neut, C.; Dubuquoy, L.; Dubuquoy, C.; Merour, E.; Geboes, K.; Chamaillard, M.; Ouwehand, A.; Leyer, G.; Carcano, D.; Colombel, J. F.; Ardid, D.; Desreumaux, P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors Nat. Med. 2007, 13, 35-37
341. Ihenetu, K.; Molleman, A.; Parsons, M. E.; Whelan, C. J. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids Eur. J. Pharmacol. 2003, 458, 207-215
342. Kimball, E. S.; Schneider, C. R.; Wallace, N. H.; Hornby, P. J. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium Am. J. Physiol.: Gastrointest. Liver Physiol. 2006, 291, G364-G371
343. Calder, V. L.; Lightman, S. L. Experimental autoimmune uveoretinitis (EAU) versus experimental allergic encephalomyelitis (EAE): a comparison of T cell-mediated mechanisms Clin. Exp. Immunol. 1992, 89, 165-169
344. Xu, H.; Cheng, C. L.; Chen, M.; Manivannan, A.; Cabay, L.; Pertwee, R. G.; Coutts, A.; Forrester, J. V. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis J. Leukocyte Biol. 2007, 82, 532-541
345. Patel, H. J.; Birrell, M. A.; Crispino, N.; Hele, D. J.; Venkatesan, P.; Barnes, P. J.; Yacoub, M. H.; Belvisi, M. G. Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation Br. J. Pharmacol. 2003, 140, 261-268
346. Belvisi, M. G.; Patel, H. J.; Freund-Michel, V.; Hele, D. J.; Crispino, N.; Birrell, M. A. Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways Br. J. Pharmacol. 2008, 155, 547-557